Neoadjuvant Therapy for HER2+ Breast Cancer
The panelists, Hope S. Rugo, MD; Adam M. Brufsky, MD; Christy A. Russell, MD; Sara A. Hurvitz, MD; and Joyce A. O’Shaughnessy, MD, elaborate on the role of HER2 inhibition in the neoadjuvant treatment of breast cancer.
